Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis

Healthy Clinical Trial

— GABAmech  

Official title:

Multi-modal Assessment of GABA Function in Psychosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04004416
• Other study ID #: HUM00162597
• Secondary ID: R01MH118634-01
• Status: Recruiting
• Phase: Phase 4
• Start date: January 16, 2020
• Est. completion date: February 28, 2025

Study information

• Verified date: November 2023
• Source: University of Michigan
• Contact: Clara Steeby, BS
• Phone: 734-615-3645
• Email: GABAStudy[@]med.umich.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to better understand mental illness and will test the hypotheses that while viewing affective stimuli, patient groups will show increased blood oxygenation level dependent (BOLD) signal by fMRI after lorazepam.

This study will enroll participants between the ages of 16 and 60, who have a psychotic illness (such as psychosis which includes conditions like schizophrenia, schizoaffective disorder, and mood disorders). The study will also enroll eligible participants without any psychiatric illness, to compare their brains.

The study will require participants to have 3-4 sessions over a few weeks. The initial assessments (may be over two visits) will include a diagnostic interview and several questionnaires (qols) to assess eligibility. Subsequently, there will will be two separate functional magnetic resonance imaging (fMRI) sessions in which lorazepam or placebo will be given prior to the MRI. During the fMRI the participants will also be asked to answer questions. Additionally, the participants will have their blood drawn, women of child bearing potential will have a urine pregnancy test, vital signs taken, and asked to complete more qols.

Description:

• Please note the collaborator (NIMH) is requesting that an NCT number be obtained prior to receiving the award number.

• Initial assessment(s) may be done via videoconference due to Covid.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 232
• Est. completion date: February 28, 2025
• Est. primary completion date: February 28, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 16 Years to 60 Years

Eligibility

Early psychosis (EP) patients:

Inclusion Criteria:

• Meets DSM5 criteria for schizophrenia, schizophreniform disorder, schizoaffective disorder, bipolar disorder type 1, with history of psychosis, major depressive disorder, with history of psychosis, brief psychotic disorder, or other specified/unspecified psychotic disorder; or, meets SIPS criteria for Presence of Psychotic Symptoms or Brief Intermittent Psychotic Syndrome (BIPS).

• Ability and willingness to give informed consent to participate;

• 16-35 years old

• Positive symptom onset = 2 years

• No history of active substance use disorder in the past 2 months

• Not currently on an involuntary treatment order

• Not taking chronic narcotics, barbiturates, benzodiazepines

• Absence of suicidal thoughts with plans or intentions, as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)

• No increases in psychotropic medication within the prior 4 weeks reflecting clinical instability and for half of EP sample, or not taking antipsychotic medication within the prior 4 weeks. Patients may take as needed doses of benzodiazepines as clinically prescribed, as long as those doses are not required within 5 half-lives of an MRI session

• Ability to tolerate small, enclosed spaces without anxiety

• No metals, implants or metallic substances within or on the body that might cause adverse effects to the subject in a strong magnetic field, or interfere with image acquisition, e. g. aneurysm clips, retained particles (metal workers excluded), neurostimulators, foil-backed transdermal patches, carotid or cerebral stents, cerebral spinal fluid (CSF)shunts; magnetic dental implants, ferromagnetic ocular implants, pacemakers, automatic implantable defibrillators

• Size compatible with scanner gantry, e. g. men over 6 feet tall that weigh more than 250 pounds (lbs), men under 6 feet tall that weigh over 220 lbs, women over 5'11" tall that weigh more than 220 lbs, or women under 5'10" tall that weigh more than 200 lbs. Subjects of these weights or greater typically have difficult fitting into the fMRI scanner properly.

Exclusion:

• If a woman of child bearing age, not pregnant or trying to become pregnant

• History of serious neurological illness or current medical condition that could compromise brain function, such as liver failure

• History of closed head injury, for example (e.g.) loss of consciousness > ~5 min, hospitalization, neurological sequela

Schizophrenia/schizoaffective (SCZ) and bipolar affective disorder (BAD) patients

Inclusion Criteria:

• Ability and willingness to give informed consent to participate;

• 16- 60 years old

• Meets DSM- 5 criteria for schizophrenia, or schizoaffective disorder, or bipolar disorder type 1, with history of psychosis bipolar affective disorder

• Duration of positive symptom onset > 2 years

• No history of active substance use disorder in the past 2 months

• Not currently on an involuntary treatment order

• Not taking chronic narcotics, barbiturates, benzodiazepines

• Absence of suicidal thoughts with plans or intentions, as assessed by C-SSRS

• No increases in psychotropic medication within the prior 4 weeks reflecting clinical instability. Patients may take as needed doses of benzodiazepines as clinically prescribed, as long as those doses are not required within 5 half-lives of an MRI session

• Ability to tolerate small, enclosed spaces without anxiety

• No metals, implants or metallic substances within or on the body that might cause adverse effects to the subject in a strong magnetic field, or interfere with image acquisition, e. g. aneurysm clips, retained particles (metal workers excluded), neurostimulators, foil-backed transdermal patches, carotid or cerebral stents, CSF shunts; magnetic dental implants, ferromagnetic ocular implants, pacemakers, automatic implantable defibrillators

• Size compatible with scanner gantry, e. g. men over 6 feet tall that weigh more than 250 lbs, men under 6 feet tall that weigh over 220 lbs, women over 5'11" tall that weigh more than 220 lbs, or women under 5'10" tall that weigh more than 200 lbs. Subjects of these weights or greater typically have difficult fitting into the fMRI scanner properly.

Exclusion:

• If a woman of child bearing age, not pregnant or trying to become pregnant

• History of serious neurological illness or current medical condition that could compromise brain function, such as liver failure

• History of closed head injury, for example (e.g.) loss of consciousness > ~5 min, hospitalization, neurological sequela

Healthy control subjects:

Inclusion Criteria:

• Ability and willingness to give informed consent to participate

• Age 16 - 60

• No history of (h/o) past or current mental illness (except for simple phobias), but prior h/o substance abuse ok if in remission for greater than 5 years

• Not taking any medication, prescription or non-prescription, with psychotropic effects (birth control medications allowed)

• No first-degree family members with a history of a psychotic disorder (including bipolar disorder)

• Ability to tolerate small, enclosed spaces without anxiety

• No metals, implants or metallic substances within or on the body that might cause adverse effects to the subject in a strong magnetic field, or interfere with image acquisition, e. g. aneurysm clips, retained particles (metal workers excluded), neurostimulators, foil-backed transdermal patches, carotid or cerebral stents, CSF shunts; magnetic dental implants, ferromagnetic ocular implants, pacemakers, automatic implantable defibrillators

• Size compatible with scanner gantry, e. g. men over 6 feet tall that weigh more than 250 lbs, men under 6 feet tall that weigh over 220 lbs, women over 5'11" tall that weigh more than 220 lbs, or women under 5'10" tall that weigh more than 200 lbs. Subjects of these weights or greater typically have difficult fitting into the fMRI scanner properly.

Exclusion:

• If a woman of child bearing age, not pregnant or trying to become pregnant

• History of serious neurological illness or current medical condition that could compromise brain function, such as liver failure

• History of closed head injury, for example (e.g.) loss of consciousness > ~5 min, hospitalization, neurological sequela

Related Conditions & MeSH terms

• Bipolar Disorder
• Healthy
• Major Depression With Psychotic Features
• Mental Disorders
• Mood Disorders
• Psychosis
• Psychotic Disorders
• Schizo Affective Disorder
• Schizophrenia
• Schizophreniform Disorders

Intervention

Other:
• Placebo and fMRI
A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.

Drug:
• Lorazepam and fMRI
A dose of Lorazepam (assigned to one of two dose levels between subjects: 0.01 mg/kg or 0.02 mg/kg) will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. There will be two fMRIs done approximately 1 week apart and after the assessment visit. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan

Sponsors (2)

Lead Sponsor	Collaborator
University of Michigan	National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood Oxygen level dependent (BOLD) in medial frontal cortex while viewing affective pictures	BOLD signal change in medial frontal cortex after lorazepam challenge during fMRI	2 hours after ingestion of lorazepam/placebo